Reduction of Hospitalization and Mortality by Echocardiography-Guided Treatment in Advanced Heart Failure

Abstract

In advanced heart failure (AHF) clinical evaluation fails to detect subclinical HF deterioration in outpatient settings. The aim of the study was to determine whether the strategy of intensive outpatient echocardiographic monitoring, followed by treatment modification, reduces mortality and re-hospitalizations at 12 months. Methods: 214 patients with ejection fraction < 30% and >1 hospitalization during the last year underwent clinical evaluation and echocardiography at discharge and were divided into intensive (IMG; N = 143) or standard monitoring group (SMG; N = 71). In IMG, volemic status and left ventricular filling pressure were assessed 14, 30, 90, 180 and 365 days after discharge. HF treatment, particularly diuretic therapy, was temporarily intensified when HF deterioration signs and E/e’ > 15 were detected. In SMG, standard outpatient monitoring without obligatory echocardiography at outpatient visits was performed. Results: We observed lower hospitalization (absolute risk reduction [ARR]-0.343, CI-95%: 0.287–0.434, p < 0.05; number needed to treat [NNT]-2.91) and mortality (ARR-0.159, CI 95%: 0.127–0.224, p < 0.05; NNT-6.29) in IMG at 12 months. One-year survival was 88.8% in IMG and 71.8% in SMG (p < 0.05). Conclusion: In AHF, outpatient monitoring of volemic status and intracardiac filling pressures to individualize treatment may potentially reduce hospitalizations and mortality at 12 months follow-up. Echocardiography-guided outpatient therapy is feasible and clinically beneficial, providing evidence for the larger application of this approach.

Ligustrazine and liguzinediol protect against doxorubicin‐induced cardiomyocytes injury by inhibiting mitochondrial apoptosis and autophagy

“…The primary pathological features of HF include inadequate cardiac output and high intracardiac pressure. 1,2 Several established risk factors, such as diet, age and genetic predisposition, have been associated with the occurrence and progression of HF. Studies have shown that excessive apoptosis of cardiomyocytes is a key pathological feature of HF, and preventing or treating HF may involve reducing cardiomyocyte death.…”

“…Heart failure (HF), the end‐stage of heart disease, is a significant public health concern and a leading cause of death worldwide. The primary pathological features of HF include inadequate cardiac output and high intracardiac pressure 1,2 . Several established risk factors, such as diet, age and genetic predisposition, have been associated with the occurrence and progression of HF.…”